Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Loncar Cancer Immunotherapy ETF (CNCR)

Loncar Cancer Immunotherapy ETF (CNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Exchange Traded Concepts
  • Assets Under Management 43,101,300
  • Market Capitalization, $K 43,101
  • Shares Outstanding, K 1,450
  • 60-Month Beta 1.28
Trade CNCR with:
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 0.35 (1.18%)
  • Most Recent Dividend 0.350 on 12/28/17
  • Management Fee 0.79%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.17 +12.93%
on 10/30/20
29.88 -1.09%
on 11/24/20
+1.59 (+5.70%)
since 10/23/20
3-Month
23.99 +23.19%
on 09/04/20
30.25 -2.29%
on 10/14/20
+3.29 (+12.52%)
since 08/24/20
52-Week
12.00 +146.28%
on 03/16/20
30.25 -2.29%
on 10/14/20
+7.39 (+33.33%)
since 11/22/19

Most Recent Stories

More News
Biotech ETFs Soar on Gilead-Immunomedics Deal

The acquisition will expand Gilead's portfolio of treatments for various types of cancer.

GILD : 60.25 (+0.60%)
IMMU : 87.86 (+0.05%)
CNCR : 29.55 (-0.61%)
XBI : 126.06 (-0.34%)
PTH : 143.66 (-2.37%)
BBC : 44.18 (+0.14%)
ETFs to Gain as AstraZeneca Resumes Coronavirus Vaccine Trial

AstraZeneca's resumption of the late-stage trials can revive investors optimism surrounding the coronavirus vaccine development.

IBB : 138.25 (-0.60%)
CNCR : 29.55 (-0.61%)
XBI : 126.06 (-0.34%)
PPH : 64.86 (+0.31%)
BBH : 157.28 (-0.84%)
7 Top ETFs That Trumped Last Week's Market Rout

Last week was extremely volatile for Wall Street with the S&P 500, the Dow Jones and the Nasdaq losing about 2.5%, 1.7% and 4.1%, respectively.

CNCR : 29.55 (-0.61%)
ITB : 56.70 (-1.73%)
PGM : 45.79 (+3.34%)
WIL : 78.93 (+1.60%)
GRU : 3.42 (+2.40%)
EPHE : 32.50 (-0.18%)
DWSH : 11.89 (-6.08%)
6 Sector ETFs Surviving the Market Rout

Amid the uncertainties, a few sectors have survived last week's turmoil. We have highlighted six of that could be compelling picks for the weeks ahead as long as volatility persists.

AZN : 53.57 (-2.07%)
CNCR : 29.55 (-0.61%)
TAN : 83.03 (+2.91%)
ITB : 56.70 (-1.73%)
RING : 27.53 (-2.69%)
MXI : 77.75 (+2.63%)
GERM : 29.11 (-1.32%)
5 ETFs Jump After Three-Day Rout: Will The Rally Last?

We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.

MSFT : 213.86 (+1.78%)
AZN : 53.57 (-2.07%)
AAPL : 115.17 (+1.16%)
TSLA : 555.38 (+6.43%)
CNCR : 29.55 (-0.61%)
PTH : 143.66 (-2.37%)
PBW : 92.18 (-0.01%)
ARKQ : 68.46 (+1.63%)
FNGS : 99.08 (+1.87%)
Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data

Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.

MRNA : 98.56 (-2.44%)
IBB : 138.25 (-0.60%)
CNCR : 29.55 (-0.61%)
XBI : 126.06 (-0.34%)
BBH : 157.28 (-0.84%)
BTEC : 53.21 (-0.62%)
IDNA : 41.51 (-0.98%)
GERM : 29.11 (-1.32%)
Moderna ETFs to Shine on U.S. Contracts for Coronavirus Vaccine

Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.

MRNA : 98.56 (-2.44%)
IBB : 138.25 (-0.60%)
CNCR : 29.55 (-0.61%)
XBI : 126.06 (-0.34%)
BBH : 157.28 (-0.84%)
BTEC : 53.21 (-0.62%)
IDNA : 41.51 (-0.98%)
GERM : 29.11 (-1.32%)
Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain

Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.

JNJ : 143.87 (unch)
AZN : 53.57 (-2.07%)
MRNA : 98.56 (-2.44%)
IBB : 138.25 (-0.60%)
CNCR : 29.55 (-0.61%)
XBI : 126.06 (-0.34%)
BBH : 157.28 (-0.84%)
IDNA : 41.51 (-0.98%)
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

AZN : 53.57 (-2.07%)
MRNA : 98.56 (-2.44%)
GSK : 37.09 (+0.95%)
NVAX : 95.33 (+1.44%)
CNCR : 29.55 (-0.61%)
INO : 10.15 (-2.22%)
PTH : 143.66 (-2.37%)
BBC : 44.18 (+0.14%)
BTEC : 53.21 (-0.62%)
ARKG : 74.72 (-3.04%)
IDN : 10.72 (+0.85%)
VXRT : 6.26 (-12.09%)
GNOM : 20.16 (-0.84%)
Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

JNJ : 143.87 (unch)
SNY : 49.92 (+0.14%)
AZN : 53.57 (-2.07%)
MRNA : 98.56 (-2.44%)
GSK : 37.09 (+0.95%)
NVAX : 95.33 (+1.44%)
IBB : 138.25 (-0.60%)
CNCR : 29.55 (-0.61%)
XBI : 126.06 (-0.34%)
BBH : 157.28 (-0.84%)
IDNA : 41.51 (-0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Fund Summary

The Loncar Cancer Immunotherapy ETF seeks investment results that correspond generally to the price and yield per for mance, before fees and expenses, of the Loncar Cancer Immunotherapy Index.

See More

Key Turning Points

2nd Resistance Point 30.04
1st Resistance Point 29.79
Last Price 29.55
1st Support Level 29.40
2nd Support Level 29.24

See More

52-Week High 30.25
Last Price 29.55
Fibonacci 61.8% 23.28
Fibonacci 50% 21.12
Fibonacci 38.2% 18.97
52-Week Low 12.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar